DOI QR코드

DOI QR Code

Co-occurrence of both maternally inherited neurofibromatosis type 1 and Lesch-Nyhan disease in a child with severe neurodevelopmental impairment

  • Jae Hun Yun (Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine) ;
  • Yong Hee Hong (Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine) ;
  • Go Hun Seo (3billion Inc.) ;
  • Young-Lim Shin (Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
  • Received : 2022.06.16
  • Accepted : 2022.10.12
  • Published : 2022.12.31

Abstract

Lesch-Nyhan disease (LND) is a rare X-linked recessive inherited purine metabolic disorder that accompanies neurodevelopmental problems. Neurofibromatosis type 1 (NF1) is a relatively common autosomal dominant inherited genetic disorder characterized by tumors in various systems. Some children with NF1 also accompanies neurodevelopmental problems. Here, we describe a 5-year-old boy with a maternally inherited pathogenic variant in NF1 and hypoxanthine-guanine phosphoribosyltransferase (HPRT). He was referred for severe neurodevelopmental impairment and hyperuricemia. His mother was diagnosed with NF1 and the patient was also suspected of having NF1 because of cafe au lait macules. He had dystonia, rigidity, cognitive deficit, and speech/language impairment. Serum and urine uric acid concentrations were elevated. He had more severe neurodevelopmental delay than patients with only NF1, so his clinical symptoms could not be fully understood by the disease alone. To find the cause of his neurologic symptoms and hyperuricemia, the patient and his mother underwent a whole-exome sequencing test. As a result, the pathogenic variant c.151C>T (p.Arg51Ter) in HPRT1 was identified as hemizygote in the patient and heterozygote in his mother. The pathogenic variant c.7682C>G (p.Ser2561Ter) in NF-1 was identified as heterozygotes in both of them. Although the clinical symptoms of both diseases were overlapping and complicated, genetic testing was helpful for accurate diagnosis and treatment. Therefore, we suggest to consider preemptive genetic evaluation if there are symptoms not sufficiently explained by known existing diseases. And it is considered valuable to review this rare case to understand the clinical course and possible synergic effects of these diseases.

Keywords

References

  1. Hoefnagel D, Andrew ED, Mireault NG, Berndt WO. Hereditary choreoathetosis, self-mutilation and hyperuricemia in young males. N Engl J Med 1965;273:130-5.  https://doi.org/10.1056/NEJM196507152730303
  2. Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med 1964;36:561-70.  https://doi.org/10.1016/0002-9343(64)90104-4
  3. Torres RJ, Puig JG. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis 2007;2:48. 
  4. Anderson LT, Ernst M, Davis SV. Cognitive abilities of patients with Lesch-Nyhan disease. J Autism Dev Disord 1992;22:189-203.  https://doi.org/10.1007/BF01058150
  5. Anderson LT, Ernst M. Self-injury in Lesch-Nyhan disease. J Autism Dev Disord 1994;24:67-81.  https://doi.org/10.1007/BF02172213
  6. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014;13:834-43.  https://doi.org/10.1016/S1474-4422(14)70063-8
  7. Vogel AC, Gutmann DH, Morris SM. Neurodevelopmental disorders in children with neurofibromatosis type 1. Dev Med Child Neurol 2017;59:1112-6.  https://doi.org/10.1111/dmcn.13526
  8. Jinnah HA. HPRT1 disorders. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., eds. GeneReviews®. Seattle (WA): University of Washington, 2020. 
  9. Visser JE, Bar PR, Jinnah HA. Lesch-Nyhan disease and the basal ganglia. Brain Res Rev 2000;32:449-75.  https://doi.org/10.1016/S0165-0173(99)00094-6
  10. Jinnah HA, Visser JE, Harris JC, Verdu A, Larovere L, Ceballos-Picot I, et al.; Lesch-Nyhan Disease International Study Group. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 2006;129(Pt 5):1201-17.  https://doi.org/10.1093/brain/awl056
  11. Jathar P, Panse AM, Jathar M, Gawali PN. Lesch-Nyhan syndrome: disorder of self-mutilating behavior. Int J Clin Pediatr Dent 2016;9:139-42.  https://doi.org/10.5005/jp-journals-10005-1350
  12. Bell S, Kolobova I, Crapper L, Ernst C. Lesch-Nyhan syndrome: models, theories, and therapies. Mol Syndromol 2016;7:302-11.  https://doi.org/10.1159/000449296
  13. Fu R, Ceballos-Picot I, Torres RJ, Larovere LE, Yamada Y, Nguyen KV, et al.; Lesch-Nyhan Disease International Study Group. Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder. Brain 2014;137(Pt 5):1282-303.  https://doi.org/10.1093/brain/awt202
  14. Pride NA, North KN. The cognitive profile of NF1 children: therapeutic implications. In: Upadhyaya M, Cooper D, eds. Neurofibromatosis type 1. Berlin: Springer, 2012;55-69. 
  15. Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol 2013;55:111-25.  https://doi.org/10.1111/j.1469-8749.2012.04399.x
  16. Gutmann DH, Parada LF, Silva AJ, Ratner N. Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci 2012;32:14087-93.  https://doi.org/10.1523/JNEUROSCI.3242-12.2012
  17. Nix JS, Blakeley J, Rodriguez FJ. An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol 2020;139:625-41.  https://doi.org/10.1007/s00401-019-02002-2
  18. Huson SM. The neurofibromatoses: classification, clinical features and genetic counselling. Monogr Hum Genet 2008;16:1-20. 
  19. Shofty B, Constantini S, Ben-Shachar S. Advances in molecular diagnosis of neurofibromatosis type 1. Semin Pediatr Neurol 2015;22:234-9. https://doi.org/10.1016/j.spen.2015.10.007